|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
|
8960834 |
1996 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Strong association between PAI-1 and the metabolic components of the insulin resistance syndrome is found in clinical studies, suggesting that insulin resistance may regulate circulating PAI-1.
|
10665338 |
1999 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
High plasma PAI-1 levels are undoubtedly related to insulin resistance, and the mechanisms which could explain such an increase in the Metabolic Syndrome appear to be multi-factorial and remain to be elucidated.
|
10867719 |
2000 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been suggested to be a part of the insulin resistance syndrome, and recent data suggest that adipose tissue participates in the production of PAI-1.
|
11025560 |
2000 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
|
11427204 |
2001 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study makes the novel observation that CRP induces PAI-1 expression and activity in HAECs and thus has implications for both the metabolic syndrome and atherothrombosis.
|
12551862 |
2003 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In 29 children and adolescents with stable renal transplants, we related plasma PAI-1 activity to an indicator of inflammatory status [plasma concentration of C-reactive protein (CRP)] and to elements of the insulin resistance syndrome [body mass index (BMI), fasting insulinemia, HOMA index and plasma triglyceride, HDL-cholesterol, apolipoproteins A-1 and B concentrations].
|
12761670 |
2003 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association between PAI-1 polymorphisms and phenotypes related to metabolic syndrome were statistically studied.
|
12856128 |
2003 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
It has gained special interest among clinicians because a number of pathological conditions, such as myocardial infarction, atherosclerosis, thrombosis, several types of cancer, and the metabolic syndrome, as well as type 2 diabetes mellitus, are associated with increased PAI-1 levels.
|
15242559 |
2004 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) plays a central role in fibrolysis and has recently been hypothesized to influence components of the insulin resistance syndrome.
|
15297806 |
2004 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that the 4G/4G PAI-1 genotype might be strongly associated with high PAI-1 levels regardless of metabolic syndrome-related variables and smoking status.
|
17199731 |
2007 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the influence of polymorphism A36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women.
|
17200772 |
2007 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Metabolic syndrome-related factors had little influence on PAI-1 levels in White subjects but in African and Indians subjects these variables had a major influence on PAI-1 levels in those with the 5G/5G genotype but not in subjects with the 4G/4G genotype.
|
17467713 |
2008 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The common promoter -675 4G/5G insertion/deletion polymorphism (indel) in the plasminogen activator inhibitor-1 (PAI-1) gene has been associated with quantitative components of the metabolic syndrome.
|
17555513 |
2007 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to investigate the effects of plasminogen activator inhibitor-1 (PAI-1) gene (SERPINE1) single nucleotide polymorphisms (SNPs) on the risk of myocardial infarction (MI), on PAI-1 levels, and factors related to the metabolic syndrome.
|
17656673 |
2007 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We observed a decreased expression of five metallothioneins, and an increased expression of liver expressed plasminogen activator inhibitor-1 protein and insulin-like growth factor II, which play a prominent role in the development of the metabolic syndrome.
|
17658692 |
2007 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Positive correlations between PAI-1 and waist circumference and BMI, and negative correlations between BMI and antioxidative defense in the pre-metabolic syndrome patients show that this early stage preceding the metabolic syndrome is also characterized by atherosclerotic complication risks and evident hyperinsulinism and insulin resistance.
|
17848118 |
2007 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since obesity and metabolic syndrome are now epidemic, and will likely have a major adverse impact on vascular thrombotic events, it may be time to test the clinical effectiveness of PAI-1 inhibition in a patient population at high risk for vascular thrombosis.
|
17896948 |
2007 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.
|
19619703 |
2009 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
|
20127289 |
2010 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, beneficial pleiotropic effects of statins on coronary artery disease may be attributable, in part, to attenuation of overexpression of PAI-1 mediated by the 3'-UTR in syndromes of insulin resistance (such as the metabolic syndrome) and type 2 diabetes.
|
20299979 |
2010 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adipose tissue macrophages: a piece of the PAI of metabolic syndrome.
|
20371488 |
2010 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.
|
21800006 |
2011 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We have investigated the expression of PAI-1, IL-6 and IL-18 in subcutaneous adipose tissue (AT) of subjects with (n = 22) and without (n = 36) MetS.
|
21842238 |
2011 |